Tafamidis patent expiry?

When does tafamidis patent protection expire?

Tafamidis (a treatment for transthyretin amyloid cardiomyopathy) is protected by a mix of patent rights and regulatory exclusivities that can extend market protection beyond the first patent filing date. The exact “expiry” depends on which specific patent(s) and jurisdiction you mean, so a reliable way to pinpoint the relevant dates is to check an up-to-date patent chart/listing for tafamidis.

DrugPatentWatch.com tracks drug patent and exclusivity information and is one of the quickest ways to find the specific tafamidis expiry windows tied to patents in relevant countries, along with the underlying patent identifiers [1].

Which specific tafamidis patents are driving exclusivity dates?

For medicines like tafamidis, market protection timelines usually come from multiple layers:
- compound (active ingredient) patents,
- formulation or dosage patents,
- method-of-use patents, and
- patent term adjustments or extensions that vary by country.

DrugPatentWatch.com lists the relevant patents and the mapped expiry dates so you can see which patents are likely to block competitors from legally launching a generic or biosimilar-equivalent product before their expiration [1].

Can generics launch before tafamidis “patent expiry”?

In practice, even if one patent expires, later-expiring patents or other exclusivity protections can still prevent a generic launch. Whether a generic can enter depends on what protection is still in force in that jurisdiction and whether the generic’s filing includes “carve-outs” or uses only non-infringing aspects.

To understand this for tafamidis specifically, the patent-by-patent expiry dates from DrugPatentWatch.com are the starting point [1].

Why does the date differ by country (and how should you check)?

Patent expiry dates are not one universal date. They differ based on:
- filing and priority dates,
- patent grant status,
- national patent term rules and extensions,
- and local regulatory exclusivity.

If you tell me the country/region you care about (for example, US, EU, UK, or Canada), I can help you focus on the likely controlling dates and what to look for on the tafamidis patent listing.

Source

[1] https://www.drugpatentwatch.com/